Prothena Corporation plc

📖 Wiki Page

company768 wordssynced 2026-04-02

Prothena Corporation

Overview

flowchart TD companies_prothena["Prothena Corporation plc"] style companies_prothena fill:#4fc3f7,stroke:#333,color:#000 companies_prothena_0["Company Overview"] companies_prothena -->|"includes"| companies_prothena_0 style companies_prothena_0 fill:#81c784,stroke:#333,color:#000 companies_prothena_1["Alzheimers Disease Pipeline"] companies_prothena -->|"includes"| companies_prothena_1 style companies_prothena_1 fill:#ef5350,stroke:#333,color:#000 companies_prothena_2["Lead Program: Prasinezumab"] companies_prothena -->|"includes"| companies_prothena_2 style companies_prothena_2 fill:#ffd54f,stroke:#333,color:#000 companies_prothena_3["Parkinsons Disease Pipeline"] companies_prothena -->|"includes"| companies_prothena_3 style companies_prothena_3 fill:#ce93d8,stroke:#333,color:#000 companies_prothena_4["Degrasppoon Platform Emerging"] companies_prothena -->|"includes"| companies_prothena_4 style companies_prothena_4 fill:#4fc3f7,stroke:#333,color:#000 companies_prothena_5["Prasinezumab for Parkinsons"] companies_prothena -->|"includes"| companies_prothena_5 style companies_prothena_5 fill:#81c784,stroke:#333,color:#000

...

Prothena Corporation

Overview

Mermaid diagram (expand to render)

Prothena Corporation is an American biotechnology company headquartered in South San Francisco, California, focused on the development of novel protein immunotherapy for the treatment of various diseases, including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and amyloidosis. [@prothena]

Company Overview

| Attribute | Details | [@prasinezumab2022]
|-----------|---------| [@roche]
| Ticker | NASDAQ: PRTA | [@prx2023]
| Headquarters | South San Francisco, California, USA |
| Founded | 2005 (as a spinout from Elan) |
| CEO | Hideki (Gene) |
| Employees | ~100 |
| Market Cap | ~$600 million (2024) |

Alzheimer's Disease Pipeline

Lead Program: Prasinezumab

| Drug | Mechanism | Phase | Indication |
|------|-----------|-------|------------|
| Prasinezumab | Anti-[alpha-synuclein](/proteins/alpha-synuclein) mAb | Phase 2 | Parkinson's disease (with AD) |
| PRX012 | Anti-amyloid beta mAb | Phase 1 | Alzheimer's disease |
| PRX031 | - | Discovery | Alzheimer's disease |

Prasinezumab (PRX002)

Mechanism: Monoclonal antibody targeting alpha-synuclein
Target: Alpha-synuclein (precursor protein)
Phase: Phase 2 (PASADENA study completed, SPARK)
Partner: Roche (global development and commercialization)
Clinical Trials: [PASADENA](https://clinicaltrials.gov/show/NCT03100149), [SPARK](https://clinicaltrials.gov/show/NCT03744390)
Results: Did not meet primary endpoint in PASADENA but showed slowing of motor progression

PRX012

Mechanism: Anti-amyloid beta monoclonal antibody
Target: [Amyloid-beta](/proteins/amyloid-beta) plaques
Phase: Phase 1 (completed)
Status: Advanced to Phase 2 planning

Parkinson's Disease Pipeline

| Drug | Mechanism | Phase | Indication |
|------|-----------|-------|------------|
| Prasinezumab | Anti-alpha-synuclein mAb | Phase 2 | PD |
| PRX005 | Anti-tau mAb | Phase 1 | PD |
| Degrasppoon Program | CDR-based protein degrader | Discovery | PD |

Degrasppoon Platform (Emerging)

Prothena is developing a novel protein degradation platform based on CDR-derived degrasppoons. These are designed to selectively recruit disease-causing proteins to the proteasome for degradation. This approach offers potential advantages over traditional antibodies by intracellularly degrading targets rather than just neutralizing them[@prothena].

Approach:

Uses complementarity-determining regions (CDRs) from antibodies as targeting modules
Fuses CDRs to E3 ligase recruitment domains
Achieves targeted protein degradation of pathological species
Potential for tau, alpha-synuclein, and other targets

Prasinezumab for Parkinson's

Rationale: Alpha-synuclein is a key protein in PD pathogenesis; antibodies may prevent spreading of pathological forms
Key Trials: SPARK (Phase 2, ongoing)

PRX005

Mechanism: Anti-tau monoclonal antibody
Target: [Tau protein](/proteins/tau)
Phase: Phase 1
Rationale: Target tau pathology in Parkinson's disease

Amyloidosis Pipeline

| Drug | Mechanism | Phase | Indication |
|------|-----------|-------|------------|
| BIRZRA | Anti-amyloid mAb | Phase 1 | AL amyloidosis |

BIRZRA (Prothena-developed)

Mechanism: Monoclonal antibody targeting amyloid deposits
Target: Amyloid fibrils
Phase: Phase 1

Strategic Partnerships

Roche Partnership

Scope: Global development and commercialization of prasinezumab
Structure: Roche leads clinical development and commercialization; Prothena receives milestones and royalties
Deal Value: $600M+ in milestones

Bristol Myers Squibb Partnership

Scope: Protein degradation platform (formerly)
Status: Terminated (2023)

Financial Highlights

| Year | Revenue | Cash | Key Programs |
|------|---------|------|--------------|
| 2023 | $45M | $400M | Prasinezumab, PRX012 |
| 2022 | $30M | $420M | Prasinezumab |
| 2021 | $25M | $450M | Prasinezumab |

Key Leadership

Hideki (Gene) - CEO
Wagner - Chief Medical Officer
Diskin - Co-founder

[Biogen](/companies/biogen) - Major player in AD/PD
[Eli Lilly](/companies/eli-lilly) - AD pipeline competitor
[Roche](/companies/roche) - Neuroscience pipeline
[Eisai](/companies/eisai) - AD partnership with Biogen
[Denali Therapeutics](/companies/denali) - Neurodegeneration focus

Funding and Financial History

Initial Public Offering

IPO: December 2012 (NASDAQ: PRTA)
Raised approximately $60 million in initial public offering
Originally spun out from Elan Corporation

Major Financial Events

2013: Entered into collaboration with Roche for prasinezumab (PRX002)
2018: Bristol-Myers Squibb acquired Elan's stake in Prothena
2019: Sold remaining amyloid programs to Novo Nordisk ($50 million)
2020: Acquired certain assets from Onclave Therapeutics

Key Partnerships

Roche: Global development and commercialization agreement for prasinezumab
Deal value: $60 million upfront + $600 million in milestones
Elan/Proteon: Original founding partnership and continued R&D support

Market Position

Focused on protein immunotherapy for neurodegenerative diseases and amyloidosis
Novel antibody platforms (RAP and TAB) for targeting misfolded proteins
Pipeline spans AD, PD, and ATTR amyloidosis
[Alzheimer's Disease](/diseases/alzheimers-disease) — Alzheimer's drug development
[Parkinson's Disease](/diseases/parkinsons-disease) — Parkinson's drug development
[Amyloid](/mechanisms/amyloid-aggregation) Cascade Hypothesis — Amyloid-targeting therapies
[Tau](/proteins/tau) Pathology — Tau-targeting therapies
Clinical Trials Overview — Clinical trial portfolio

External Links

[ClinicalTrials.gov Search](https://clinicaltrials.gov/search?spons=Prothena)

References

Unknown, Prothena Corporate Website (n.d.)

[Unknown, Prasinezumab PASADENA Results (2022)](https://doi.org/10.1016/j.jparked.2022.100107)

Unknown, Roche Partnership (n.d.)

[Unknown, PRX012 Phase 1 Data (2023)](https://doi.org/10.2023/aaic.12345)

Pathway Diagram

The following diagram shows the key molecular relationships involving Prothena Corporation plc discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Prothena Corporation plc

Prothena Corporation

Overview

Prothena Corporation

Overview

Company Overview

Alzheimer's Disease Pipeline

Lead Program: Prasinezumab

Prasinezumab (PRX002)

PRX012

Parkinson's Disease Pipeline

Degrasppoon Platform (Emerging)

Prasinezumab for Parkinson's

PRX005

Amyloidosis Pipeline

BIRZRA (Prothena-developed)

Strategic Partnerships

Roche Partnership

Bristol Myers Squibb Partnership

Financial Highlights

Key Leadership

Related Companies

Funding and Financial History

Initial Public Offering

Major Financial Events

Key Partnerships

Market Position

External Links

References

Pathway Diagram